About this trial
Enhanced external counterpulsation (EECP) is a noninvasive, non-pharmacologic intervention proven to increase nitric oxide bioavailability in patients with coronary artery disease. Although EECP showed short-term effects in improving coronary flow in patients with coronary slow flow, whether such improvement is durable remains uncertain, and the relationships between such improvement and changes in multiple organ functions as well as inflammatory markers have not been elucidated. The purpose of this study will be to evaluate the potential clinical benefits of EECP on organ function and proinflammatory cytokine concentrations during post-acute sequela of cardiovascular surgery.
Eligibility criteria
Qualifiers
Age > 18 years;
Patients with Stable angina pectoris, unstable angina pectoris, acute myocardial infarction, congestive heart failure, cardiogenic shock;
Patients chronic heart failure;
Patients are ready to received cardiovascular surgery during this hospital admission.
Disqualifiers
None
Trial design
Treatments tested in this trial
- Enhanced External Counterpulsation (EECP)
- Sham Comparator
Treatment groups
Sponsors and collaborators
Nanjing Medical University
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Collaborator